Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of ARGX-113 in generalized myasthenia gravis
2016-002938-73Phase 2Completed
- Sponsor
- argenx
- Start
- Sep 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myasthenia gravis (MG) comparing ARGX-113 with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events. Started Sep 2016; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2016-002938-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002938-73.